AnaptysBio, Inc. (ANAB)

NASDAQ: ANAB · Real-Time Price · USD
15.51
-7.58 (-32.83%)
At close: Dec 11, 2024, 4:00 PM
15.70
+0.19 (1.23%)
Pre-market: Dec 12, 2024, 8:33 AM EST
-32.83%
Market Cap 471.95M
Revenue (ttm) 57.17M
Net Income (ttm) -165.66M
Shares Out 30.43M
EPS (ttm) -6.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,092,754
Open 14.32
Previous Close 23.09
Day's Range 14.20 - 16.93
52-Week Range 14.20 - 41.31
Beta -0.13
Analysts Buy
Price Target 54.89 (+253.9%)
Earnings Date Nov 5, 2024

About ANAB

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and I... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 26, 2017
Employees 117
Stock Exchange NASDAQ
Ticker Symbol ANAB
Full Company Profile

Financial Performance

In 2023, AnaptysBio's revenue was $17.16 million, an increase of 66.78% compared to the previous year's $10.29 million. Losses were -$163.62 million, 27.1% more than in 2022.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for ANAB stock is "Buy." The 12-month stock price forecast is $54.89, which is an increase of 253.90% from the latest price.

Price Target
$54.89
(253.90% upside)
Analyst Consensus: Buy
Stock Forecasts

News

AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data

On Wednesday, AnaptysBio, Inc. ANAB announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the ARISE-AD trial as a monot...

18 hours ago - Benzinga

AnaptysBio to abandon eczema drug development after mid-stage trial failure

AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a mid-stage trial, the company said on Wednesday, dragging its shares nearly 4...

22 hours ago - Reuters

AnaptysBio abandons eczema drug development after mid-stage trial failure

AnaptysBio said on Wednesday that it would discontinue the development of its eczema drug after it failed to meet the main and secondary goals of a mid-stage trial.

23 hours ago - Reuters

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that inve...

1 day ago - GlobeNewsWire

Anaptys Announces Participation in November and December Investor Conferences

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani...

5 weeks ago - GlobeNewsWire

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial ...

5 weeks ago - GlobeNewsWire

Anaptys Announces Participation in September Investor Conferences

SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani...

3 months ago - GlobeNewsWire

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point

AnaptysBio, Inc. 14-week results from the phase 2b study, using ANB032 for the treatment of patients with moderate-to-severe Atopic Dermatitis, expected in December 2024. The global Atopic dermatitis ...

4 months ago - Seeking Alpha

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi Led by long-standing investor EcoR1 Capital with participation from addition...

4 months ago - GlobeNewsWire

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update

SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial ...

4 months ago - GlobeNewsWire

AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst

HC Wainwright analyst initiated coverage on AnaptysBio Inc ANAB, a clinical-stage biotechnology company focused on delivering immunology therapeutics.

5 months ago - Benzinga

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial r...

7 months ago - GlobeNewsWire

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced positive t...

7 months ago - GlobeNewsWire

Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the execut...

7 months ago - GlobeNewsWire

Actym Therapeutics Appoints Thomas Smart as CEO

BERKELEY, Calif. , April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer.

Other symbols: PGENXOMA
8 months ago - PRNewsWire

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating...

9 months ago - GlobeNewsWire

Anaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual Meeting

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani...

10 months ago - GlobeNewsWire

Anaptys to Present at Guggenheim's 6th Annual Biotechnology Conference

SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani...

11 months ago - GlobeNewsWire

Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced an exclus...

1 year ago - GlobeNewsWire

Anaptys Named a BioSpace 2024 Best Places to Work Winner

SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that, for...

1 year ago - GlobeNewsWire

Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating ...

1 year ago - GlobeNewsWire

Anaptys Announces Participation in November Investor Conferences

SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani...

1 year ago - GlobeNewsWire

Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced two upcom...

1 year ago - GlobeNewsWire

AnaptysBio's skin disease drug meets main goal in late-stage study

AnaptysBio Inc said on Monday its experimental drug to treat a type of rare skin disease met the main goal in a late-stage study.

1 year ago - Reuters

Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25

SAN DIEGO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will h...

1 year ago - GlobeNewsWire